ClinicalTrials.gg

Program

PF-07832837

A development code.

In Pfizer's pipeline, undisclosed. Its studies are mostly in Dermatitis, Atopic, led by Pfizer.

Furthest: phase 1, since Aug 19, 20241 company-led study, 1 open or runningNext primary completion: Jun 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Aug 19, 2024Aug 19, 2024Jun 2, 2027phase 1 · NCT06564389
  • Named in Pfizer’s own pipeline as PF-07832837, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06564389 · 119 planned · United States, Poland

Ahead

  1. Jun 2, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT06564389

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“undisclosed”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06564389Dermatitis, Atopic · United States, Poland1RecruitingJun 2, 2027119

How it is read

Names in the registry

  • “PF-07832837”, 1 entry

Codes read as this program: PF07832837.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.